Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acorda R&D Day Explores Pipeline Opportunities

This article was originally published in The Pink Sheet Daily

Executive Summary

Acorda Therapeutics highlighted the other indications it has in the works for its MS drug Ampyra, as well as several early-stage compounds in other neurological indications.

You may also be interested in...

Acorda Drops Epilepsy Candidate Once Central To Its Revenue Forecasts

Plumiaz, a nasal spray formulation of diazepam, is discontinued after it fails one of three Phase III trials undertaken to comply with 2014 FDA complete response letter.

Second Quarter Earnings Calls, In Brief

As second quarter earnings announcement shift into high gear, companies announce changes to manufacturing, progress on their drug launch efforts and their intentions to ramp up business development efforts.

Acorda Expands Pipeline With Neuronex And New Ampyra Indications

Acorda Therapeutics reports strong Ampyra results in the fourth quarter and highlights the other indications it’s pursuing for the drug, as well as the consumer marketing campaign the company is about to undertake. Acorda also announced its intention to acquire privately-held Neuronex Inc. for $2 million upfront plus $500,000 in R&D funding.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts